<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>6759814</identifier>
<setSpec>0210-5187</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>De Sambricio Guiú, F</dc:author>
<dc:author>Del Pino Gamboa, J</dc:author>
<dc:author>Colomo Gómez, C</dc:author>
<dc:description xml:lang="en">It is presented a comparative and clinical study on 37 patients affected by psoriasis, 13 of them took placebo and 22 finished treatment with Anapsos in capsules of 120 mg. One patient abandoned treatment by intolerance and another one with possible laryngeal neoplasm, the drug showed a discordant result. 9 out of 22 who used anapsos, obtained full whitening, 5 got whitenings between 40% and 80% of the affected surface, 5 got a maximum of 40% and 3 had null result. The absence of side effects, minimum intolerance of product and the amount of obtained successes make the authors to consider the future of anapsos optimistically for the treatment of psoriasis.</dc:description>
<dc:type>Clinical Trial</dc:type>
<dc:language>es</dc:language>
<dc:date>1982 </dc:date>
<dc:title xml:lang="es">Estudio comparativo entre anapsos 120 mg. y un placebo en 37 enfermos de psoriasis.</dc:title>
<dc:title xml:lang="en">[Comparative study between 120 mg. of anapsos and a placebo in 37 psoriasis patients].</dc:title>
<dc:publisher>Medicina cutanea ibero-latino-americana</dc:publisher>
</metadata>
</record>
</pubmed-document>
